Tesaro Inc. (NASDAQ:TSRO) – Stock analysts at FBR & Co increased their FY2019 earnings estimates for shares of Tesaro in a research note issued on Tuesday. FBR & Co analyst E. White now expects that the firm will post earnings of $2.39 per share for the year, up from their prior forecast of $1.36. FBR & Co has a “Outperform” rating and a $115.00 price objective on the stock.
Several other brokerages have also recently weighed in on TSRO. Zacks Investment Research raised Tesaro from a “sell” rating to a “hold” rating in a research note on Tuesday, July 5th. SunTrust Banks Inc. reaffirmed a “buy” rating and set a $91.60 target price on shares of Tesaro in a research note on Wednesday, September 14th. Wedbush reaffirmed a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Credit Suisse Group AG reaffirmed an “outperform” rating and set a $122.00 target price (up previously from $90.00) on shares of Tesaro in a research note on Monday. Finally, Robert W. Baird raised their target price on Tesaro from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday. One analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $110.11.
Tesaro (NASDAQ:TSRO) traded down 0.95% on Friday, hitting $115.05. 728,964 shares of the stock were exchanged. The company’s 50-day moving average is $98.99 and its 200-day moving average is $70.75. The company’s market cap is $5.91 billion. Tesaro has a 52 week low of $29.51 and a 52 week high of $122.89.
Tesaro (NASDAQ:TSRO) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.71) by $0.43. Tesaro had a negative net margin of 783.97% and a negative return on equity of 205.63%. The company earned $36.60 million during the quarter, compared to the consensus estimate of $4.98 million. During the same quarter in the prior year, the company posted ($1.51) EPS.
In other news, SVP Martin H. Jr. Huber sold 408 shares of the firm’s stock in a transaction dated Thursday, September 22nd. The stock was sold at an average price of $108.12, for a total transaction of $44,112.96. Following the completion of the sale, the senior vice president now directly owns 1,250 shares of the company’s stock, valued at approximately $135,150. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Jeffrey H. Hanke sold 29,166 shares of the firm’s stock in a transaction dated Tuesday, August 30th. The stock was sold at an average price of $86.04, for a total value of $2,509,442.64. Following the sale, the vice president now directly owns 29,166 shares of the company’s stock, valued at $2,509,442.64. The disclosure for this sale can be found here. Insiders own 40.50% of the company’s stock.
Several large investors have recently bought and sold shares of TSRO. BlackRock Fund Advisors increased its stake in Tesaro by 1.8% in the first quarter. BlackRock Fund Advisors now owns 1,293,906 shares of the biopharmaceutical company’s stock worth $56,971,000 after buying an additional 23,384 shares during the period. BlackRock Inc. increased its stake in Tesaro by 13.3% in the first quarter. BlackRock Inc. now owns 7,096 shares of the biopharmaceutical company’s stock worth $312,000 after buying an additional 834 shares during the period. venBio Select Advisor LLC purchased a new stake in Tesaro during the first quarter worth $6,605,000. Pictet Asset Management Ltd. increased its stake in Tesaro by 35.8% in the first quarter. Pictet Asset Management Ltd. now owns 55,000 shares of the biopharmaceutical company’s stock worth $2,225,000 after buying an additional 14,500 shares during the period. Finally, Emerald Acquisition Ltd. purchased a new stake in Tesaro during the second quarter worth $23,685,000. 88.81% of the stock is owned by institutional investors.